Antibody–Peptide Conjugates (APCs) represent a powerful approach for targeted biologic modulation, and AMG 133 has demonstrated compelling clinical potential in obesity treatment. This case study showcases how a complex APC was successfully synthesized with precise control and exceptional product quality—enabling robust functional performance while overcoming key development hurdles.

Highlights

• Controlled, High Homogeneity Conjugation: Achieved defined DAR with outstanding monomer purity, ensuring consistent product quality.
• Efficient & Rapid Process: From linker peptide assembly to final purification, the workflow delivered material suitable for advanced studies.
• Functional Integrity Confirmed: The conjugate exhibited expected receptor activity, validating correct mechanism and bioactivity.
• Supports Challenging APC Development: Demonstrates practical solutions to conjugation efficiency, stability, and manufacturing complexity.

Download the full case study to see how we deliver high quality APCs with confidence.